Glaukos Corporation
RHO KINASE INHIBITOR RELEASING IMPLANTS AND RELATED METHODS OF USE

Last updated:

Abstract:

The present disclosure is directed to intracameral implants for treating and/or preventing corneal disorders, diseases, and/or conditions, such as corneal endothelial dystrophies. The intracameral implants can be configured to provide a sustained release of a therapeutic agent, such as a Rho kinase inhibitor, for a prolonged period of time. The intracameral implants can include a non-bioresorbable anchor or a bioresorbable matrix.

Status:
Application
Type:

Utility

Filling date:

2 Jun 2021

Issue date:

9 Dec 2021